Li et al. compared and investigated the treatment regimens used for diabetes in relation to the rate of pancreatic carcinogenesis, and reported that while insulin analogs and insulin secretagogues increased the risk of pancreatic cancer onset in diabetic patients by approximately 4.99-fold and 2.52-fold, respectively. Here, INS is linked to diabetes mellitus.